Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii

M. S. Bartlett, T. D. Edlind, M. M. Durkin, M. M. Shaw, S. F. Queener, J. W. Smith

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Nine antimicrotubule benzimidazole derivatives tested in a Pneumocystis carinii culture system with human embryonic lung fibroblast monolayers inhibited organism proliferation. The concentrations of drugs inhibitory in culture ranged from 10 to 0.1 μg/ml, with thiabendazole being the least effective (10 μg/ml) and parbendazole being the most effective (0.1 μg/ml). The parent compound, benzimidazole, was inactive at 10 μg/ml. Demonstration that this group of compounds has activity against P. carinii provides a new potential target that can be exploited, the microtubules. Also, the variability in the effectiveness of the compounds provides the basis for studies of structure-activity relationships, which were initiated in this study.

Original languageEnglish (US)
Pages (from-to)779-782
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number4
DOIs
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii'. Together they form a unique fingerprint.

  • Cite this